Orthofix (NSDQ:OFIX) announced today that Intersect ENT (NSDQ:XENT) executive Thomas A. West has joined its board of directors.
Lewisville, Texas-based Orthofix named West to its board and appointed him to its Compensation and Talent Development Committee.
West currently serves as President, CEO & Director of Intersect ENT, which develops drug-delivery devices for ear, nose and throat procedures. He has navigated the company through its recently announced $1.1 billion acquisition by Medtronic.
Before Intersect ENT, West was Division President of Diagnosis Solutions at Hologic. Before that, he had a 23-year stint at Johnson & Johnson in various domestic and international roles. West’s most recent position was Worldwide VP of Strategy & Business Development a Diabetes Solutions Companies.
“Tom joins the Orthofix Board of Directors with more than 30 years of global experience in the medical device industry,” Orthofix Chair of the Board Catherine Burzik said in a news release. “We feel his vast experience will benefit Orthofix by providing international and domestic insights and guidance as we grow globally. We are very pleased he has chosen to join our board.”
